Durvalumab (anti-PD-L1)

目录号：A2013         批次号: A201307

打印

Durvalumab (anti-PD-L1)是一种IgG1κ单抗，抑制PD-L1与PD-1/CD80 (B7.1)的相互作用。MW=146.3 kDa。

抗体信息

CAS号 1428935-60-7
配制 100 mM Pro-Ac, 20 mM Arg, pH 5.0
推荐同型对照 Human IgG1
来源 CHO cells
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
除菌 0.2 μM filtered
纯度 99%
蛋白浓度 9.35mg/ml
内毒素 ＜1EU/mg

客户使用selleck产品的实验数据

Durvalumab (anti-PD-L1)在文献中得到引用

PPP2R1A mutations portend improved survival after cancer immunotherapy [ Nature, 2025, 10.1038/s41586-025-09203-8] PubMed: 40604275
PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC [ J Biomed Sci, 2025, 32(1):94] PubMed: 41068729
Macrophage-derived pro-inflammatory cytokines augment the cytotoxicity of cytokine-induced killer cells by strengthening the NKG2D pathway in multiple myeloma [ Sci Rep, 2025, 15(1):16739] PubMed: 40369131
Antigenic cancer persister cells survive direct T cell attack [ bioRxiv, 2025, 2025.03.14.643359] PubMed: 40166148
Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia [ Pharmacol Res, 2024, 199:107048] PubMed: 38145833
Polymer-based antibody mimetics (iBodies) target human PD-L1 and function as a potent immune checkpoint blocker [ J Biol Chem, 2024, S0021-9258(24)01826-X] PubMed: 38685532
Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab [ Am J Nucl Med Mol Imaging, 2024, 14(1):31-40] PubMed: 38500749
Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune-checkpoint inhibitor monoclonal antibody used for immunotherapy of lung cancer [ Heliyon, 2023, 9(6):e15782] PubMed: 37389074
Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune [ Heliyon, 2023, 9(6):e15782.] PubMed: 37389074
Novel highly sensitive chemiluminescence immunoassay for quantitation of durvalumab, an immune-checkpoint inhibitor monoclonal antibody used for [ Talanta Open, 2023, Volume 7, 100219] PubMed: None

禁止用于人体及治疗！